ORAMED PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ORAMED PHARMACEUTICALS INC. (ORMP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.00 million for the 9-month period ending 2014-05-31, per its 10-Q filed 2014-07-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2014-07-14
- ORAMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2014-05-31 was $727.61K.
- ORAMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2014-02-28 was $75.26K.
- ORAMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2013-11-30 was $200.86K, a 5.61% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2013-08-31 was $75.93K, a 36.92% decline year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 65 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 101 month |
|---|---|---|---|---|---|---|---|
| 2014-05-31 | $727.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-07-14 | $802.88K derived: sum of 2 quarters · filed 2014-07-14 | $1.00M 10-Q · filed 2014-07-14 | $1.08M derived: sum of 4 quarters · filed 2014-07-14 | |||
| 2014-02-28 | $75.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-10 | $276.12K 10-Q · filed 2014-04-10 | $352.05K derived: sum of 3 quarters · filed 2014-04-10 | ||||
| 2013-11-30 | $200.86K 10-Q · filed 2014-01-14 | $276.79K derived: sum of 2 quarters · filed 2014-04-10 | |||||
| 2013-08-31 | $75.93K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-04-10 | $562.97K 10-Q · filed 2014-04-10 | |||||
| 2013-05-31 | $487.03K 10-Q · filed 2013-07-17 | ||||||
| 2012-11-30 | $190.19K 10-Q · filed 2012-12-26 | $310.57K derived: sum of 2 quarters · filed 2014-04-10 | $324.92K derived: sum of 3 quarters · filed 2014-04-10 | $346.26K derived: sum of 4 quarters · filed 2014-04-10 | |||
| 2012-08-31 | $120.37K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-04-10 | $134.73K derived: sum of 2 quarters · filed 2014-04-10 | $156.07K derived: sum of 3 quarters · filed 2014-04-10 | $200.87K 10-Q · filed 2014-04-10 | $275.24K 10-K · filed 2012-12-12 | ||
| 2012-05-31 | $14.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-07-12 | $35.70K derived: sum of 2 quarters · filed 2012-07-12 | $80.49K 10-Q · filed 2012-07-12 | ||||
| 2012-02-29 | $21.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-04-04 | $66.14K 10-Q · filed 2012-04-04 | |||||
| 2011-11-30 | $44.79K 10-Q · filed 2012-01-12 | ||||||
| 2011-08-31 | $502.59K 10-Q · filed 2014-04-10 | ||||||
| 2010-08-31 | $690.88K 10-Q · filed 2014-04-10 | $3.55M 10-Q · filed 2012-07-12 | |||||
| 2009-08-31 | $436.02K 10-Q · filed 2014-04-10 | ||||||
| 2008-08-31 | $459.47K 10-Q · filed 2014-04-10 | ||||||
| 2007-08-31 | $1.97M 10-Q · filed 2014-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |